Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
NewLeaf Symbiotics
AddedFeb 15, 2024
UpdatedJun 18, 2026
NewLeaf Symbiotics

NewLeaf Symbiotics

NewLeaf Symbiotics: An agri-biotech firm innovating plant health and yield with beneficial bacteria.

HQ
St. Louis, MO, US
Founded
2012
Overview
Compare
Fundraising
Employees
Website

NewLeaf Symbiotics, founded with a mission to revolutionize agriculture through biotechnology, focuses on enhancing plant health and crop yield using beneficial bacteria known as PPFMs (Pink Pigmented Facultative Methylotrophs). The company develops and commercializes these bacteria, which are naturally occurring and promote early growth and increased yield in crops. NewLeaf's products, including the EPA-registered bioinsecticide TS201, are marketed across the United States and aim to integrate seamlessly into existing pest management systems.

Notable figures affiliated with NewLeaf Symbiotics include experienced agricultural scientists and biotech industry veterans. The company has secured investments from prominent venture capital firms, enabling significant research and development advancements. Key achievements include the successful registration of their bioinsecticide with the EPA and the widespread adoption of their products by farmers. NewLeaf Symbiotics has made a substantial impact on sustainable agriculture by providing innovative solutions that enhance crop productivity and resilience.

NewLeaf Symbiotics - Quick Facts

When was NewLeaf Symbiotics founded?

NewLeaf Symbiotics was founded in 2012.

Where is NewLeaf Symbiotics' headquarters located?

NewLeaf Symbiotics' headquarters is located in St. Louis, MO, US.

When was NewLeaf Symbiotics' last funding round?

NewLeaf Symbiotics' most recent funding round was for $47M (USD) in December 2023.

How much has NewLeaf Symbiotics raised to-date?

As of Dec 19, 2023, NewLeaf Symbiotics has raised a total of $134.6M (USD).

How many employees does NewLeaf Symbiotics have?

NewLeaf Symbiotics has 45 employees as of Feb 5, 2024.

NewLeaf Symbiotics - Classification

Industry
  • Agriculture
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Licensing
  • Recurring
  • Software
  • Transactional
Customer
  • Enterprise
Main Product
  • Bioinsecticides
  • Crop Protection
Tags
  • AgTech
  • Biotech
NAICS
  • 320000Manufacturing
  • 325300Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing
  • 325320Pesticide and Other Agricultural Chemical Manufacturing
  • 325000Chemical Manufacturing
SIC
  • 2870Agricultural Chemicals
  • 2879Pesticides And Agricultural Chemicals, Not Elsewhere Classified
  • 2800Chemicals And Allied Products
ISIC
  • 4330Building completion and finishing
Show 9 more industry codes
NAICS
  • 230000Construction
  • 238000Specialty Trade Contractors
  • 238300Building Finishing Contractors
  • 238330Flooring Contractors
SIC
  • 1700Construction-special Trade Contractors
  • 1750Carpentry And Floor Work
  • 1752Floor Laying And Other Floor Work, Not Elsewhere Classified
  • 2890Miscellaneous Chemical Products
  • 2899Chemicals And Chemical Preparations, Not Elsewhere Classified